The Beginning
In 1988 Reaven (1) formalized the concept that insulin resistance clusters with glucose intolerance, dyslipidemia, and hypertension to enhance cardiovascular disease (CVD) risk. These abnormalities did not just segregate with insulin resistance but were related to it by cause-effect relationships, some clearer than others and many still undergoing active investigation. In other words, much less a probabilistic phenomenon than a mechanistic theory: the insulin resistance syndrome (IRS). In IRS, the primacy of insulin resistance ( Fig.  1) is posited on the grounds that insulin resistance is an effective transducer of environmental influences, with obesity (especially visceral) (2), cardiorespiratory fitness (3), and stress (4) being the most important ones. On the effector side, insulin exerts potent actions not only in pathways in glucose homeostasis but also on lipid turnover, blood pressure control, and vascular reactivity (nonglucose actions in Fig. 1 ). Moreover, chronic hyperinsulinemia-the in vivo adaptive response to insulin resistance-has been shown to have pathogenic potential in its own right [for example, by downregulating insulin action (5), strengthening antinatriuresis (6), or stimulating the adrenergic nervous system (7)], thereby creating reinforcement circuits in the network (8) . These facts are supported by a wealth of experimental and clinical investigation (extensively reviewed in Ref. 9 ). However, it is crucial to emphasize that just as insulin resistance alone is insufficient to alter glucose tolerance-for which some degree of ␤-cell dysfunction is required-insulin resistance/hyperinsulinemia is neither strictly necessary nor sufficient to alter lipid metabolism, blood pressure, or vascular function. Each of these homeostatic systems is under multifactorial control, and defects in one or more steps of its effector pathway (other factors in Fig. 1 ) are necessary to drive the system out of control. Also, each of these systems is redundant, with plenty of interactions. For example, a genetic deficiency in glucokinase (or lipoprotein lipase) expression can be enough to impair glucose tolerance (or triglyceride metabolism), and at the same time induce insulin resistance (secondary to glucotoxicity or substrate competition, respectively): the resulting pathophysiological picture would be indistinguishable from one of primary insulin resistance.
Thus, the proper domain of IRS is pathophysiology (hatched area in Fig. 1 ): a network in which pulling one node or arm out of the normal boundaries will drag other nodes and arms into the pathological range or just below it. A pathophysiological syndrome will result, with a composition presumably rather variable from case to case depending on the initiating event(s).
The Follow-Up
In the 1990s, the pathophysiological IRS transmuted into the clinical metabolic syndrome. What caused this shift? Was it because eminent scientific societies rushed out all-purpose definitions or because of the vested interests of the pharmaceutical industry? Was it disease mongering [akin to other, proven or suspected, cases (10) ]? While these factors may have played some part, the driving motive may have been less ignoble.
In fact, hyperinsulinemia predicts diabetes, dyslipidemia (11) , and, to a lesser extent, hypertension (12) , and is an independent, if weak, CVD predictor (13): the question arises, can one exploit IRS to anticipate and, hopefully, prevent disease? In this case, new knowledge generates a legitimate inquiry; after all, scientists are increasingly expected to try and translate science into practice in areas of major medical and social concern. If this was the project, however, it has gone somewhat astray.
Measuring insulin resistance directly (by the glucose clamp technique) is difficult; at the population level, it has been performed only in a few hundred Pima Indians followed-up for some years (14) . Using fasting plasma insulin levels as a proxy for insulin resistance introduces confounding, because of the partly different physiology of hyperinsulinemia and insulin resistance (15) , as well as lack of measurement standardization across studies. These practical hurdles have prompted the search for cheap, easy surrogates of insulin resistance: among them, the waist girth or the waist-to-hip ratio seemed best in certain epidemiological studies (16) . Thus, anthropometric measures have tended to replace insulin resistance in new definitions of the syndrome before research could conclusively establish whether these traits are equivalent or distinct and, in the latter case, how so in relation to the components of the cluster. A protean "metabolic syndrome" has then morphed out through different definitions (World Health Organization, National Cholesterol Education Program-Adult Treatment Panel, International Diabetes Federation, etc.) adopting mixtures of anthropometric, pathophysiological, and clinical criteria: predictors (waist girth, insulin, triglycerides) and outcomes (diabetes, hypertension) have been dichotomized (thresholds rather than continuous variables), assembled (any two of three or three of five criteria), and even prioritized (e.g. waist girth first, then any two of three) in somewhat arbitrary fashion.
Next, the temptation to reanalyze available datasets with incident diabetes or CVD as the outcome by using some definition (or multiple definitions) of the syndrome as the risk factor has been difficult to resist. The literature has been flooded with epidemiological analyses purporting to show an independent predictivity of one or the other metabolic syndrome for incident diabetes and CVD (Ͼ17,000 PubMed entries).
The final turn has been to upgrade the metabolic syndrome to disease status-certified with a classification code (first in the United States, next in Europe)-and then propel it into the clinical arena worldwide, where, as my intern attested, it has been received with much favor.
Results
Current evidence suggests the following. 1) The stability of the metabolic syndrome over time is ill defined. It may display a relatively high rate of spontaneous regression (as is the case with impaired glucose tolerance). In the only relevant study (17) , the prevalence of the metabolic syndrome did not increase in Mexico City between 1990 and 1992 and 1997 and 1999 despite increasing central obesity.
2) The metabolic syndrome offers little substantial advantage in CVD risk prediction over available algorithms (e.g. the Framingham score). A careful meta-analysis has shown that, depending on definition (and modifications thereof), sample size, subject selection, duration of follow-up, outcome event, and type of statistical analysis, using the metabolic syndrome as a predictor may provide some improvement in risk assessment (18) . To predict diabetes, however, the current definitions of metabolic syndrome do not offer any significant advantage over other algorithms (19, 20) (although they efficiently detect impaired glucose tolerance) (21). 3) Which component of the syndrome carries what weight has not been established. 4) That the syndrome as a whole counts more than the sum of its parts is still unproven.
Last, it is popular to claim that the concept of the metabolic syndrome has been, and continues to be, very useful to the medical community to enhance awareness of risk clustering and to promote thorough screening in individuals presenting a CVD risk factor. Whereas this benefit sounds likely, to my knowledge no study has formally addressed this issue; diverting attention from major, established CVD risk may actually be a possible untoward consequence of focusing on the metabolic syndrome.
The Prospect
If someone presents with overt diabetes, hypertension, and dyslipidemia, one can certainly call that metabolic syndrome regardless of any specific criteria or definition. It would, however, be an abbreviation, not a diagnosis; prognosis and treatment of that metabolic syndrome would be today what they were before metabolic syndrome was undeservedly granted a disease code.
It remains possible that some combination of subclinical abnormalities, more or less closely related to insulin resistance/hyperinsulinemia/visceral obesity, may signal a significant surplus of CVD risk that is not predicted by the classical risk engines (Framingham, UKPDS, PROCAM, etc. ). This hypothesis must be rigorously tested with the use of powerful tools: extensive datasets, robust statistical models, and cross-validation. Picking out predictors from the physical/lifestyle domain (e.g. waist circumference as a proxy of visceral adiposity, resting heart rate as a proxy of cardiorespiratory fitness, etc.) and/or from the large pool of biochemical markers (e.g. C-reactive protein, adiponectin, highdensity lipoprotein cholesterol, triglycerides, ApoA/ApoB ratio, fibrinogen, etc.) does not require assumptions about etiology or pathogenesis. So long as the aim is to configure a risk syndrome (22) , all that matters is the ability of its components to consistently and substantially contribute to eroding unexplained CVD risk. Hypothesis testing should, in my opinion, involve the following steps (see Table 1 ): 1) The Note that genetic influences are not indicated because they apply to each element in the schema. CR fitness, Cardiorespiratory fitness; Endoth. Dysfun., endothelial dysfunction. See text for further explanation. Ferrannini • Metabolic Syndromepurpose of the syndrome, whether prediction of diabetes or CVD, should be specified.
2) The criteria should be unambiguously defined (23) . 3) Physiological parameters should not be dichotomized unless independent evidence proves the existence of a threshold in their relation to risk. 4) Modeling should explore nonlinearities and weighting. 5) Established predictors (e.g. age, familial diabetes, or premature cardiovascular disease, etc.) should be included in the model. Of special import would be to arrive at the proof that the cluster is stronger than the sum of its components. This would be an emergent property: behavior that is not fully predicted by structure, like brain function (24) . Such a result would imply that some risk factors act not in an additive but multiplicative fashion. For example, having an abnormal lipid profile may amplify CVD risk in a hypertensive individual (e.g. the notion of familial dyslipidemic hypertension) (25) .
Once a general risk engine capable of capturing cardiometabolic risk with high specificity and accuracy is compiled and validated in multiple datasets from different populations, it could be reduced to a clinical algorithm by peeling off complex or costly measures in a statistically controlled fashion (26) .
Whereas not yet a disease, a risk syndrome identified by this tool would definitely serve the purpose of designing preventive measures. In addition, it would fertilize pharmaceutical research, as new drugs may target the cluster rather than one or the other of its components. Typically, insulin sensitizers or weight-reducing agents may hit nodal points of the cluster (insulin resistance and ectopic fat, respectively), thereby improving multiple abnormalities. The clinical algorithm could prove useful to monitor efficacy and time course of new treatments.
The point is, the task still waits to be completed. Should it succeed, we will have a name for it: metabolic syndrome. 
